Clinical Trial Update: TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant therapy consisting of TACE or ablation plus Sintilimab and Ipilimumab for resectable hepatocellular carcinoma with interm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepato Cellular Carcinoma (HCC) | Phase 2 | Status: NOT_YET_RECRUITING